Seng Yong Chun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seng Yong Chun has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Hee Ho Chu
Department of Radiology, Asan Medical Center, University of Ulsan, Seoul 05505, Republic of Korea
1 shared publication - Ji Hoon Shin
Department of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
1 shared publication - Jihoon Kim
Department of Radiology, Asan Medical Center, University of Ulsan, Seoul 05505, Republic of Korea
1 shared publication - Jin Hyoung Kim
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 16 June 2026
- Published by MDPI AG in Preprints.org
Transarterial Drug Eluting Chemoembolization for Patients with Hepatocellular Carcinoma in Korea Using the Transradial Approach (ThinkRADIAL Study)
Background/Objectives: To evaluate the technical feasibility, safety, and therapeutic outcomes of the transradial approach for drug-eluting bead transarterial chemoembo-lization (DEB-TACE) as a patient-centric alternative to the conventional transfemoral route. Methods: Between August 2018 and August 2022, patients with unresectable hepato-cellular carcinoma (HCC) eligible for DEB-TACE were prospectively enrolled in this study (ClinicalTrials.gov identifier: NCT07160374). To prevent radial artery spasm and occlusion, a standardized intra-arterial cocktail solution containing 3,000 IU of heparin, 200 μg of nitroglycerin, and 2.5 mg of verapamil was administered immediately after sheath insertion. The primary endpoint was technical success without crossover to the femoral approach. Secondary endpoints included safety profile, tumor response, and procedural parameters. Results: A total of 37 patients were enrolled. Technical success was achieved in 100% of patients using the transradial approach, with zero crossover to the transfemoral ap-proach. A single major adverse event (liver abscess) occurred (2.7%). Radial artery pa-tency was preserved in all patients. All patients achieved immediate post-procedural ambulation. The objective response rate was 73% at first follow-up visit (median, 35 days; range, 14–60 days). The mean fluoroscopy time was 24 ± 9 minutes, and the mean dose area product was 142 ± 182 Gy·cm². Conclusions: The transradial approach demonstrated high technical success and a fa-vorable safety profile for DEB-TACE without increasing radiation exposure. These findings suggest that this method represents a feasible and effective alternative to the conventional transfemoral route.
- 16 June 2026
- Published by MDPI AG in Preprints.org
Open AccessTransarterial Drug Eluting Chemoembolization for Patients with Hepatocellular Carcinoma in Korea Using the Transradial Approach (ThinkRADIAL Study)
Background/Objectives: To evaluate the technical feasibility, safety, and therapeutic outcomes of the transradial approach for drug-eluting bead transarterial chemoembo-lization (DEB-TACE) as a patient-centric alternative to the conventional transfemoral route. Methods: Between August 2018 and August 2022, patients with unresectable hepato-cellular carcinoma (HCC) eligible for DEB-TACE were prospectively enrolled in this study (ClinicalTrials.gov identifier: NCT07160374). To prevent radial artery spasm and occlusion, a standardized intra-arterial cocktail solution containing 3,000 IU of heparin, 200 μg of nitroglycerin, and 2.5 mg of verapamil was administered immediately after sheath insertion. The primary endpoint was technical success without crossover to the femoral approach. Secondary endpoints included safety profile, tumor response, and procedural parameters. Results: A total of 37 patients were enrolled. Technical success was achieved in 100% of patients using the transradial approach, with zero crossover to the transfemoral ap-proach. A single major adverse event (liver abscess) occurred (2.7%). Radial artery pa-tency was preserved in all patients. All patients achieved immediate post-procedural ambulation. The objective response rate was 73% at first follow-up visit (median, 35 days; range, 14–60 days). The mean fluoroscopy time was 24 ± 9 minutes, and the mean dose area product was 142 ± 182 Gy·cm². Conclusions: The transradial approach demonstrated high technical success and a fa-vorable safety profile for DEB-TACE without increasing radiation exposure. These findings suggest that this method represents a feasible and effective alternative to the conventional transfemoral route.